Recanalization Therapy for Acute Ischemic Stroke with Large Vessel Occlusion: Where We Are and What Comes Next?

Transl Stroke Res · 2021 · PMC8055567 · PMID 33409732

Europe PMC DOI

hedged sentences

0.0430

closest p · 0.9× alpha

0.0430

boldest claim

The sentences

marginal significancep = 0.043actually significant

Despite the encouraging results of PROACT-II, the US FDA did not approve IA treatment of AIS with r-proUK based on the small sample size, marginal significance ( p = 0.043), and approval for IV tPA treatment.

also in 5,069 other papers

showed a trendno p-value reported

In the phase II RHAPSODY trial, 3K3A-APC, a recombinant variant of human activated protein C (APC), in combination with thrombolysis and EVT, showed a trend towards reduced hemorrhage [ 114 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.